Dominik Kołodziejek

Dominik Kołodziejek

Auto-generated profile, based on publicly available information

Dominik Kołodziejek

Faculty of Chemistry, Warsaw University of Technology, 3 Noakowskiego Street, 00-664 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Polymer Testing
Verified
Journal Article
Open access
DKDominik Kołodziejek
Dominik Kołodziejek
IŁIwona Łopianiak
Iwona Łopianiak
OTOliwia Tadko
Oliwia Tadko
MDMarcin Drozd
Marcin Drozd
Michał WojasińskiMichał Wojasiński
Michał Wojasiński
EJElżbieta Jastrzębska
Elżbieta Jastrzębska

23 April 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
AKAnna Kobuszewska
Anna Kobuszewska
DKDominik Kolodziejek
Dominik Kolodziejek
Michał WojasińskiMichał Wojasiński
Michał Wojasiński
TCTomasz Ciach
Tomasz Ciach
Zbigniew BrzozkaZbigniew Brzozka
Zbigniew Brzozka
EJElżbieta Jastrzębska
Elżbieta Jastrzębska
Regenerative medicine and stem cells could prove to be an effective solution to the problem of treating heart failure caused by ischemic heart disease. However, further studies on the understanding of the processes which occur during the regeneration of damaged tissue are needed. Microfluidic systems, which provide conditions similar to in vivo, could be useful tools for the development of new therapies using stem cells. We investigated how mesenchymal stem cells (MSCs) affect the metabolic activity of cardiac cells (rat cardiomyoblasts and human cardiomyocytes) incubated with a potent uncoupler of mitochondrial oxidative phosphorylation under microfluidic conditions. A cyanide p-trifluoromethoxyphenylhydrazone (FCCP) was used to mimic disfunctions of mitochondria of cardiac cells. The study was performed in a microfluidic system integrated with nanofiber mats made of poly-l-lactid acid (PLLA) or polyurethane (PU). The microsystem geometry allows four different cell cultures to be conducted under different conditions (which we called: normal, abnormal—as both a mono- and co-culture). Metabolic activity of the cells, based on the bioluminescence assay, was assessed in the culture’s performed in the microsystem. It was proved that stem cells increased metabolic activity of cardiac cells maintained with FCCP.

18 September 2025 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
KDKołodziejek Dominik
Kołodziejek Dominik
SASzlachetka Aleksandra
Szlachetka Aleksandra
IZIwoń-Szczawińska Zuzanna
Iwoń-Szczawińska Zuzanna
MDMarcin Drozd
Marcin Drozd
Michał WojasińskiMichał Wojasiński
Michał Wojasiński
EJElżbieta Jastrzębska
Elżbieta Jastrzębska
Over the years, cardiovascular diseases have remained a leading cause of mortality worldwide, necessitating advanced experimental models to mimic the natural environment of the heart as closely as possible. New microfluidic heart models would enable precise modelling of the healthy heart as well as pathological mechanisms occurring during cardiac ischemia and testing new therapies would become more accessible than it is currently. In this study, we developed a two layer holder for creating hypoxic conditions in a dedicated microfluidic system for modelling cardiac infarction. By integrating the holder with a microsystem utilizing nanofibrous mats with iron(II, III) oxide (Fe3O4) magnetic nanoparticles we were able to create a tool for using (potentially patient specific) induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in cardiac research. In the microsystem we induced hypoxia and conducted preliminary observations of cardiac regeneration using induced pluripotent stem cells (iPSCs). We found that iPSCs express cTnT when co-cultured with hypoxia-damaged iPSC-CMs indicating that the holder with an integrated microsystem can be used for hypoxia and cardiac regeneration studies.

22 April 2026 in ACS Omega
Verified
Journal Article
Open access
PBPatrycja Baranowska
Patrycja Baranowska
BŁBartłomiej Łuszczuk
Bartłomiej Łuszczuk
DKDominik Kołodziejek
Dominik Kołodziejek
JTJakub, Waldemar Trzciński
Jakub, Waldemar Trzciński
WŚWeronika Świtlik
Weronika Świtlik
EJElżbieta JastrzęBska
Elżbieta JastrzęBska
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, with a five year survival rate below 10%. The high mortality rate of PDAC is primarily due to its aggressive metastatic nature, late diagnosis, and resistance to available therapies. A strategic research direction that demands significantly more attention is the identification of novel tumor markers and the development of tools for rapid, noninvasive diagnosis of this type of cancer. Circulating tumor cells (CTCs) are a promising target for early cancer detection via liquid biopsy, but their clinical application in PDAC is limited due to their rarity and technical challenges in reliable isolation and analysis. CTCs are typically isolated based on physical properties (size, density, deformability, charge, shape, hydrodynamics) or antigenic markers using specific antibodies. Although numerous cancer-specific antibodies have been identified, a marker uniquely distinguishing PDAC has yet to be found. In this work, we present the latest results concerning the development of a microfluidic platform that enables effective immunomagnetic isolation of PDAC cells from a complex biological sample using two potential PDAC markers: Plectin-1 and EpCAM. Here, we developed a low-cost, easy-to-manufacture, and user-friendly 3D-printed microfluidic platform that integrates a micromixer and a separation chamber for rapid cell isolation. Optimization tests showed that Plectin-1 at a concentration of 0.485 μg/mL captured 102 cells/ml with a recovery of 80% ± 13.3%, EpCAM at a concentration of 0.625 μg/mL captured 103 cells/ml with a recovery of 47% ± 13.3%, and the mixture of EpCAM and Plectin-1 at concentrations of 0.3125 μg/mL and 0.242 μg/mL, respectively, achieved a recovery of 91.3% ± 4.4%. To demonstrate the applicability of the method in biological samples, blood with different anticoagulants was tested. The highest detection sensitivity was achieved in the blood sample with citrate: Plectin-1 at 0.485 μg/mL enabled detection at a concentration of 102 cells/ml (47 ± 9% recovery), and EpCAM at 1.25 μg/mL achieved a 92 ± 8% recovery. The entire isolation process from biological samples was performed in less than 1 min. Using this system combined with antibody-functionalized magnetic nanoparticles targeting EpCAM and Plectin-1, we demonstrated the efficient capture of PDAC cells from biological samples, highlighting Plectin-1 as a promising PDAC marker and the potential of immunomagnetic microfluidic separation for improved diagnostics.